MSN Largely Loses On US Cabometyx Patents But Dodges Infringement Charge
Second Portion Of Patent-Infringement Proceedings Eliminates Potential For Early Launch
MSN Laboratories returned to court to attack more US patents shielding Exelixis’ blockbuster oncology drug Cabometyx. However, as with the first ruling, the Indian firm was met with further disappointment.
